Harbeck N - Search Results

1

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.

Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U, Harbeck N. Gluz O, et al. Among authors: harbeck n. J Clin Oncol. 2009 Dec 20;27(36):6144-51. doi: 10.1200/JCO.2008.19.6261. Epub 2009 Nov 9. J Clin Oncol. 2009. PMID: 19901122 Clinical Trial.

2

Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.

Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jürchott K, Schmitt M, Royer HD. Janz M, et al. Among authors: harbeck n. Int J Cancer. 2002 Jan 20;97(3):278-82. doi: 10.1002/ijc.1610. Int J Cancer. 2002. PMID: 11774277

3

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA. Look MP, et al. Among authors: harbeck n. J Natl Cancer Inst. 2002 Jan 16;94(2):116-28. doi: 10.1093/jnci/94.2.116. J Natl Cancer Inst. 2002. PMID: 11792750 Free article.

4

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

Harbeck N, Kates RE, Schmitt M. Harbeck N, et al. J Clin Oncol. 2002 Feb 15;20(4):1000-7. doi: 10.1200/JCO.2002.20.4.1000. J Clin Oncol. 2002. PMID: 11844823

5

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA. Harbeck N, et al. Cancer Res. 2002 Aug 15;62(16):4617-22. Cancer Res. 2002. PMID: 12183417

6

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

7

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Zemzoum I, et al. Among authors: harbeck n. J Clin Oncol. 2003 Mar 15;21(6):1022-8. doi: 10.1200/JCO.2003.04.170. J Clin Oncol. 2003. PMID: 12637466

8

Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.

Roggel F, Hocke S, Lindemann K, Sinz S, Welk A, Bosl M, Pabst M, Nusser N, Braun S, Schmitt M, Harbeck N. Roggel F, et al. Among authors: harbeck n. Recent Results Cancer Res. 2003;162:89-100. doi: 10.1007/978-3-642-59349-9_8. Recent Results Cancer Res. 2003. PMID: 12790324 Review.

9

Advanced statistical methods for the definition of new staging models.

Kates R, Schmitt M, Harbeck N. Kates R, et al. Among authors: harbeck n. Recent Results Cancer Res. 2003;162:101-13. doi: 10.1007/978-3-642-59349-9_9. Recent Results Cancer Res. 2003. PMID: 12790325 Review.

10

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.

Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Fred Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder M, Manders P, Edward Fiets W, Blankenstein M, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex L, Klijn J, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens J. Look M, et al. Among authors: harbeck n. Thromb Haemost. 2003 Sep;90(3):538-48. doi: 10.1160/TH-02-11-0264. Thromb Haemost. 2003. PMID: 12958624

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

718 results

Search Page

Filters